Skip to main content

Table 3 Independent predictors for progression-free and overall survival

From: Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization

Variables Progression-free survival Overall survival
  Univariate Multivariate Univariate Multivariate
  P value P value HR 95% CI P value P value HR 95% CI
Age, years 0.770   - - 0.578   - -
Male 0.028 0.443 - - 0.013 0.039 2.119 1.040-4.320
Etiology         
Viral vs. others 0.252   - - 0.916   - -
Anti-viral therapy 0.325   - - 0.047 0.453 - -
HBV-DNA positivity 0.165   - - 0.231   - -
HBeAg positivity 0.234   - - 0.324   - -
Child-Pugh class, A vs. B 0.040 0.832 - - 0.787   - -
Liver cirrhosis 0.101   - - 0.002 0.005 2.319 1.281-4.201
GGT 0.001 0.012 1.003 1.001-1.004 0.014 0.068 - -
Tumor marker         
Baseline AFP 0.008 0.049 1.000 1.000-1.001 0.486   - -
Baseline DCP 0.039 0.686 - - 0.001 0.028 1.000 1.000-1.001
AFP response 0.155   - - 0.023 <0.001 0.276 0.147-0.518
DCP response 0.756   - - 0.205   - -
BCLC stage, A vs. ≥B 0.002 0.409 - - 0.003 0.502 - -
Number of tumora 0.001 0.373 - - <0.001 0.030 1.443 1.035-2.011
Size of Tumorb 0.021 0.927 - - <0.001 0.085 - -
WHO response         
CR + PR + SD vs. PD 0.419   - - 0.945   - -
mRECIST         
CR + PR + SD vs. PD 0.107   - - 0.548   - -
  1. anumber of measurable lesion, btotal size of measurable lesion.
  2. HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; DCP, des gamma carboxy prothrombin; BCLC, Barcelona Clinic Liver Cancer.
  3. Reference value: others, Child-Pugh class B, BCLC stage ≥ B, PD with WHO criteria, and PD with mRECIST criteria.